Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a malignant solid tumor. In recent years, although immune check point inhibitors (ICIs) have achieved important advances in the treatment of SCLC, immune-related adverse events (irAEs) have occurred at the same time during the therapeutic period. Some irAEs lead to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wanting, Zhou, Xiaohan, Yi, Cheng, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016392/
https://www.ncbi.nlm.nih.gov/pubmed/33816235
http://dx.doi.org/10.3389/fonc.2021.604227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016392/
https://www.ncbi.nlm.nih.gov/pubmed/33816235
http://dx.doi.org/10.3389/fonc.2021.604227

Ejemplares similares